Keybank National Association OH Has $622,000 Stock Holdings in Penumbra, Inc. $PEN

Keybank National Association OH trimmed its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 48.9% in the first quarter, Holdings Channel.com reports. The fund owned 1,894 shares of the company’s stock after selling 1,811 shares during the quarter. Keybank National Association OH’s holdings in Penumbra were worth $622,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in PEN. Artisan Partners Limited Partnership lifted its holdings in shares of Penumbra by 165.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 594,112 shares of the company’s stock valued at $184,715,000 after acquiring an additional 370,636 shares during the period. William Blair Investment Management LLC acquired a new stake in shares of Penumbra during the 4th quarter worth about $107,567,000. Holocene Advisors LP acquired a new stake in shares of Penumbra during the 3rd quarter worth about $78,585,000. Man Group plc lifted its holdings in Penumbra by 1,862.2% during the 2nd quarter. Man Group plc now owns 206,461 shares of the company’s stock valued at $52,984,000 after purchasing an additional 195,939 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in Penumbra by 139.4% in the second quarter. AQR Capital Management LLC now owns 330,990 shares of the company’s stock valued at $84,939,000 after buying an additional 192,734 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Penumbra Price Performance

Penumbra stock opened at $317.43 on Thursday. The business’s 50-day simple moving average is $320.88 and its 200 day simple moving average is $329.77. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. The stock has a market cap of $12.48 billion, a price-to-earnings ratio of 73.14, a P/E/G ratio of 1.97 and a beta of 0.70. Penumbra, Inc. has a 12-month low of $221.26 and a 12-month high of $362.41.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The business had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. During the same quarter in the prior year, the firm earned $0.83 EPS. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. As a group, research analysts anticipate that Penumbra, Inc. will post 5.04 earnings per share for the current year.

Analyst Ratings Changes

PEN has been the topic of several research analyst reports. Citigroup decreased their price objective on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research note on Thursday, May 7th. Zacks Research downgraded Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Evercore reaffirmed an “outperform” rating and set a $320.00 price target on shares of Penumbra in a report on Monday. Wall Street Zen raised Penumbra to a “hold” rating in a research note on Saturday, May 9th. Finally, Royal Bank Of Canada restated a “sector perform” rating and issued a $374.00 target price on shares of Penumbra in a research note on Thursday, June 11th. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $360.33.

Penumbra Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.